menu
    • menu
    [{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Not Applicable"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Minerva Biotechnologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"huMNC2-CAR44 CAR T cells","moa":"MUC1","graph1":"Oncology","graph2":"Phase I","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Minerva Biotechnologies","highestDevelopmentStatusID":"6","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Minerva Biotechnologies"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Diaprost","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"h5A10","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Diaprost","highestDevelopmentStatusID":"4","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Diaprost"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Seneca Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Seneca Valley virus-001","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Seneca Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Seneca Therapeutics"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"OTQ923","moa":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Not Applicable"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Caribou Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"Anti-CD371 scFvs based cell therapy","moa":"CD371","graph1":"Oncology","graph2":"Preclinical","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Caribou Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Caribou Biosciences"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Errant Gene Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Autologous CD34+ cells","moa":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Sellas Life Sciences Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Galinpepimut-S","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Abintus Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Agreement","leadProduct":"In Vivo CAR-X Products","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Eureka Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"TCR Mimic CAR-T Cell Therapy","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Y-mAbs Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"GD2-SADA","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Y-mAbs Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Naxitamab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"12","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Sellas Life Sciences Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Galinpepimut-s","moa":"WT1","graph1":"Oncology","graph2":"Phase III","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"10","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Sellas Life Sciences Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"Galinpepimut-S","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Alaya.bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"CAR-T Cell Therapy","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"OSE Immunotherapeutics SA","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"CAR-T Based Therapy","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"AbSci","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Antibody-based Therapy","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"3","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Memorial Sloan Kettering Cancer Center"}]

    Find Clinical Drug Pipeline Developments & Deals by Memorial Sloan Kettering Cancer Center

    Menu

    Memorial Sloan Kettering Cancer Center

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Memorial Sloan Kettering Cancer Center

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Memorial Sloan Kettering Cancer Center

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antibody-based Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Recipient : AbSci

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Absci Teams with Global Cancer Center to Discover Therapeutics Using Generative AI

                            Details : The collaboration unites Absci’s Generative AI Drug Creation Platform with leading oncology experts to discover and develop up to six novel cancer therapeutics.

                            Product Name : Undisclosed

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            August 12, 2024

                            Lead Product(s) : Antibody-based Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Recipient : AbSci

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Memorial Sloan Kettering Cancer Center

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Memorial Sloan Kettering Cancer Center

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CAR-T Based Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : OSE Immunotherapeutics SA

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            OSE Immunotherapeutics Announces CAR T-cell Therapies Agreement

                            Details : This new agreement is based on the initial multi-year research collaboration between MSK and OSE Immunotherapeutics to explore the preclinical potential against IL-7R Acute Lymphoblastic Leukemia.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            June 24, 2024

                            Lead Product(s) : CAR-T Based Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : OSE Immunotherapeutics SA

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Memorial Sloan Kettering Cancer Center

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Memorial Sloan Kettering Cancer Center

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CAR-T Cell Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Alaya.bio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Alaya.Bio Announces Collaboration with Top Global Cancer Center for In Situ CAR-T Therapy

                            Details : The collaboration will advance research into in situ CAR-T cell therapies and evaluate their potential to deliver faster, more effective, and cost-efficient treatments for patients.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            January 18, 2024

                            Lead Product(s) : CAR-T Cell Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Alaya.bio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Memorial Sloan Kettering Cancer Center

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Memorial Sloan Kettering Cancer Center

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Galinpepimut-S,Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Sellas Life Sciences Group

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            SELLAS Life Sciences Reports Positive Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo i...

                            Details : SLS-001 (galinpepimut-S) is an immunotherapeutic which targets the Wilms Tumor 1 (WT1) protein and which is investigated in Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma.

                            Product Name : SLS-001

                            Product Type : Vaccine

                            Upfront Cash : Not Applicable

                            June 28, 2023

                            Lead Product(s) : Galinpepimut-S,Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Sellas Life Sciences Group

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Memorial Sloan Kettering Cancer Center

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Memorial Sloan Kettering Cancer Center

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Galinpepimut-s

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : Sellas Life Sciences Group

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            SELLAS Life Sciences Announces Update on Phase 3 REGAL Clinical Trial Evaluating Lead Asset, Galinpepimut-S, i...

                            Details : Galinpepimut-S (GPS) is an immunotherapeutic which targets the Wilms Tumor 1 (WT1) protein which is present and over-expressed in an array of hematological malignancies and solid tumors.

                            Product Name : SLS-001

                            Product Type : Vaccine

                            Upfront Cash : Not Applicable

                            November 14, 2022

                            Lead Product(s) : Galinpepimut-s

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Sellas Life Sciences Group

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Memorial Sloan Kettering Cancer Center

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Memorial Sloan Kettering Cancer Center

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Naxitamab,GM-CSF

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Recipient : Y-mAbs Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Y-mAbs Announces Regulatory Filing for DANYELZA® (naxitamab-gqgk) in Brazil

                            Details : DANYELZA (naxitamab-gqgk) is indicated, in combination with granulocyte-macrophage colony-stimulating factor for treatment of pediatric patients 1 year of age and older and adult patients.

                            Product Name : Danyelza

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 26, 2022

                            Lead Product(s) : Naxitamab,GM-CSF

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Recipient : Y-mAbs Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Memorial Sloan Kettering Cancer Center

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Memorial Sloan Kettering Cancer Center

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GD2-SADA,177Lu-DOTA

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Y-mAbs Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Y-mAbs' Announces Clearance of IND for GD2-SADA

                            Details : The GD2-SADA construct was created using our SADA technology, utilizes a pre-targeted payload delivery method where antibody constructs assemble in tetramers and bind to the tumor target.

                            Product Name : GD2-SADA

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 12, 2022

                            Lead Product(s) : GD2-SADA,177Lu-DOTA

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Y-mAbs Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Memorial Sloan Kettering Cancer Center

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Memorial Sloan Kettering Cancer Center

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TCR Mimic CAR-T Cell Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Eureka Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Eureka Therapeutics Announces Publication of Study Demonstrating Broad Anti-Tumor Activity of TCR Mimic-Redire...

                            Details : In the study, anti-NDC80 TCRm-redirected T cells demonstrated high specificity in recognizing and killing multiple cancer cell lines. Moreover, no toxicities to healthy leukocytes and hematopoietic stem cells were observed.

                            Product Name : NDC80

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            June 06, 2022

                            Lead Product(s) : TCR Mimic CAR-T Cell Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Eureka Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Memorial Sloan Kettering Cancer Center

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Memorial Sloan Kettering Cancer Center

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : In Vivo CAR-X Products

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Abintus Bio

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Abintus Bio Enters Technology Agreement to Enhance In Vivo-Reprogrammed CAR Cell Potency and Durability Agains...

                            Details : Under the terms of agreement, Memorial Sloan Kettering Cancer Center will use of its next generation signaling technology (“1XX”) in Abintus’ In Vivo CAR-X products.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            November 17, 2021

                            Lead Product(s) : In Vivo CAR-X Products

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Abintus Bio

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Memorial Sloan Kettering Cancer Center

                            U.S.A arrow
                            BePharma
                            Not Confirmed

                            Memorial Sloan Kettering Cancer Center

                            U.S.A arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Galinpepimut-S,Nivolumab,Sargramostim

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Sellas Life Sciences Group

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            SELLAS Reports Encouraging Updated Clinical Data from Ongoing Mesothelioma Study of Galinpepimut-S (GPS) Combi...

                            Details : The safety profile of the GPS-nivolumab combination was similar to that seen with nivolumab alone, with the addition of only low-grade, temporary local reactions at the GPS injection site, consistent with previously performed clinical studies with GPS.

                            Product Name : SLS-001

                            Product Type : Vaccine

                            Upfront Cash : Not Applicable

                            June 24, 2021

                            Lead Product(s) : Galinpepimut-S,Nivolumab,Sargramostim

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Sellas Life Sciences Group

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth